Navigation Links
Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response

l protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. The most serious adverse events associated with ABRAXANE in the randomized metastatic breast cancer study for which FDA approval was based included neutropenia, anemia, infections, sensory neuropathy, nausea, vomiting, and myalgia/arthralgia. Other common adverse reactions included anemia, asthenia, diarrhea, ocular/visual disturbances, fluid retention, alopecia, hepatic dysfunction, mucositis, and renal dysfunction. For the full prescribing information for ABRAXANE(R), please visit www.abraxane.com.

ABRAXANE was developed by Abraxis BioScience, Inc. ABRAXANE is marketed in the United States under a co-promotion agreement between Abraxis BioScience, Inc. and AstraZeneca Pharmaceuticals LP.

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE(R), was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on The Nasdaq Global Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com.

FORWARD-LOOKING STATEMENT

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securitie
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
2. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw ... with accompanying instrumentation to place and insert the screw ... soft tissue (e.g. ligament) repair or reconstruction as it ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... Panasonic Healthcare Group today announced a new distribution ... for the hearing professional, which will allow licensed ... www.panasonic-hearingshop.com .  This is the first time ... for hearing care professionals to order online.    ...
... CHICAGO, Feb. 10, 2012  Zacks highlights commentary from People and ... http://photos.prnewswire.com/prnh/20101027/ZIRLOGO ) For more Voice of the ... Market Percolates, Doubters Wait They,re ... of course the troll community. They,re telling you the market ...
Cached Medicine Technology:Panasonic Reaches Distribution Agreement With The Hearing Shop 2Panasonic Reaches Distribution Agreement With The Hearing Shop 3Panasonic Reaches Distribution Agreement With The Hearing Shop 4Zacks' Voice of the People highlights opportunities with Walgreen, Occidental Petroleum and Brown & Brown 2Zacks' Voice of the People highlights opportunities with Walgreen, Occidental Petroleum and Brown & Brown 3
(Date:7/9/2014)... , , , , ... , , , , ... 50m downrange from the firer and approximately 30cm from the bullet... , , ... , , , , , ... , , , , , , University of Southampton researchers, ...
(Date:7/9/2014)... School of Medicine of the University of Southern ... specific component of the immune system are completely ... infection. The discovery suggests that blocking this immune ... autoimmune and hyper-inflammatory diseases such as rheumatoid arthritis ... published online on June 23 in The ...
(Date:7/8/2014)... Department of Defense,s Defense Advanced Research Projects Agency ... to $2.5 million to develop an implantable neural ... neurons within the brain to help restore memory, ... builds on the understanding that memory is a ... the brain encode information, store it and retrieve ...
(Date:7/8/2014)... 2014 In a study published yesterday in the ... La Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify ... currently affects over 200 million people world wide. , ... be divided into small sections or ,neighborhoods., Scientists can ... primed for gene production, by looking for a marker on ...
(Date:7/8/2014)... new NPR/Robert Wood Johnson Foundation/Harvard School of Public Health ... stress in Americans, lives finds that about half of ... stressful event or experience in the past year. Nearly ... to health. , More than half of those who ... month say too many overall responsibilities and financial problems ...
Breaking Medicine News(10 mins):Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3Health News:LJI develops new approach to identify genes poised to respond in asthma patients 2Health News:Poll finds health most common major stressful event in Americans' lives last year 2Health News:Poll finds health most common major stressful event in Americans' lives last year 3Health News:Poll finds health most common major stressful event in Americans' lives last year 4
... ... international events for Valentine,s weekend in Las Vegas: The USA ... the Power Pilates "Power Higher" Conference will host Pilates professionals worldwide. ... teams, Pilates professionals and thousands of spectators from around the world ...
... from the Cleveland Clinic found that the overall mortality ... rheumatic diseases was not worse than the age and ... reported in previous studies of rheumatic diseases and conditions ... study appear in the February issue of Arthritis ...
... , Jan. 27 Ms. Lorren ... issued the following statement in advance of the President,s ... more than 150 public, private, and voluntary organizations dedicated to ... viral hepatitis that afflicts more than 5 million Americans: , ...
... had brain or other central nervous system cancers, or ... public, according to an article published online January 27 ... . This study was undertaken because previous studies ... had contradictory findings, or were not population-based. E.R. ...
... from diabetes, according to a prospective study of Group ... kidney failure or blindness, the result of small vessel ... heart attack or stroke. The findings were published ... journal of the American Diabetes Association. The study was ...
... Study suggests higher cost-sharing for outpatient visits may increase ... Boosting co-pays for doctor visits and other outpatient care ... may have the unintended consequence of sharply increasing hospitalizations, ... end up inflating overall health-care spending and put vulnerable ...
Cached Medicine News:Health News:Rugby & Pilates Have a Date for Valentine's Weekend in Vegas 2Health News:Rugby & Pilates Have a Date for Valentine's Weekend in Vegas 3Health News:Rugby & Pilates Have a Date for Valentine's Weekend in Vegas 4Health News:Rugby & Pilates Have a Date for Valentine's Weekend in Vegas 5Health News:Mortality rates for pediatric rheumatology patients significantly lower than previously reported 2Health News:NVHR Issues Challenge to Administration, Congress: Don't Leave 5 Million Americans Afflicted with Chronic Viral Hepatitis Out in the Cold with Budget Freeze 2Health News:NVHR Issues Challenge to Administration, Congress: Don't Leave 5 Million Americans Afflicted with Chronic Viral Hepatitis Out in the Cold with Budget Freeze 3Health News:Severe complications of diabetes higher in depressed patients 2Health News:Raising Co-Pays for Doctor Visits Raises Seniors' Hospital Use 2Health News:Raising Co-Pays for Doctor Visits Raises Seniors' Hospital Use 3
The BluefishRx ICD-9 is a Palm OS code lookup tool which incorporates the ICD-9 code set with the full and short code descriptions. It includes a multi keyword search tool with a dictionary of over 2...
MD Coder v 6.0 is a charge capture for the Palm OS and Pocket PC operating systems. We have integrated the feedback from hospitals and physicians. MD Coder v 6.0 comes in three versions: Physician Ba...
Preferred Health Resourses Practice Management System is called Remedy. The PDA version is Remedy for the Palm. It is a data capture program for your medical billing....
ZapICD is a reference to the complete set of ICD codes....
Medicine Products: